Tarsus Pharmaceuticalsinc Stock Buy Hold or Sell Recommendation
| TARS Stock | USD 36.85 0.18 0.49% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Tarsus PharmaceuticalsInc is 'Strong Sell'. Macroaxis provides Tarsus PharmaceuticalsI buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TARS positions. The advice algorithm takes into account all of Tarsus PharmaceuticalsI's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Tarsus PharmaceuticalsI's buy or sell advice are summarized below:
Real Value 37.92 | Target Price 46 | Hype Value 36.59 | Market Value 36.85 | Naive Value 37.01 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Tarsus PharmaceuticalsInc given historical horizon and risk tolerance towards Tarsus PharmaceuticalsI. When Macroaxis issues a 'buy' or 'sell' recommendation for Tarsus PharmaceuticalsInc, the advice is generated through an automated system that utilizes algorithms and statistical models.
Tarsus |
Execute Tarsus PharmaceuticalsI Buy or Sell Advice
The Tarsus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Tarsus PharmaceuticalsInc. Macroaxis does not own or have any residual interests in Tarsus PharmaceuticalsInc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Tarsus PharmaceuticalsI's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Tarsus PharmaceuticalsI Trading Alerts and Improvement Suggestions
| Tarsus PharmaceuticalsI had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 17.45 M. Net Loss for the year was (135.89 M) with loss before overhead, payroll, taxes, and interest of (17.76 M). | |
| Tarsus PharmaceuticalsInc currently holds about 245.36 M in cash with (117.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2. | |
| Tarsus PharmaceuticalsI has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Favourable Signals For Tarsus Pharmaceuticals Numerous Insiders Acquired Stock |
Tarsus PharmaceuticalsI Returns Distribution Density
The distribution of Tarsus PharmaceuticalsI's historical returns is an attempt to chart the uncertainty of Tarsus PharmaceuticalsI's future price movements. The chart of the probability distribution of Tarsus PharmaceuticalsI daily returns describes the distribution of returns around its average expected value. We use Tarsus PharmaceuticalsInc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Tarsus PharmaceuticalsI returns is essential to provide solid investment advice for Tarsus PharmaceuticalsI.
| Mean Return | 0.54 | Value At Risk | -5.54 | Potential Upside | 6.72 | Standard Deviation | 4.13 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Tarsus PharmaceuticalsI historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Tarsus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tarsus PharmaceuticalsI is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tarsus PharmaceuticalsInc backward and forwards among themselves. Tarsus PharmaceuticalsI's institutional investor refers to the entity that pools money to purchase Tarsus PharmaceuticalsI's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Polygon Management Ltd | 2023-12-31 | 800 K | Nantahala Capital Management, Llc | 2023-12-31 | 750.6 K | State Street Corporation | 2023-12-31 | 674.8 K | Geode Capital Management, Llc | 2023-12-31 | 609.7 K | Ikarian Capital, Llc | 2023-12-31 | 518.5 K | Goldman Sachs Group Inc | 2023-12-31 | 474.9 K | Ensign Peak Advisors Inc | 2023-12-31 | 437.9 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 430.1 K | Artisan Partners Limited Partnership | 2023-12-31 | 390 K | Rtw Investments, Llc | 2023-12-31 | 3.2 M | Blackrock Inc | 2023-12-31 | 2.5 M |
Tarsus PharmaceuticalsI Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (175K) | (456K) | (586K) | (144.1M) | 35.5M | 37.3M | |
| Change In Cash | 55.6M | 110.2M | 3.2M | (99.7M) | 153.3M | 161.0M | |
| Free Cash Flow | (3.8M) | (21.6M) | 3.2M | (49.5M) | (123.0M) | (116.8M) | |
| Depreciation | 37K | 96K | 312K | 325K | 877K | 920.9K | |
| Capital Expenditures | 175K | 456K | 586K | 506K | 5.5M | 5.8M | |
| Net Income | (4.7M) | (26.8M) | (13.8M) | (62.1M) | (135.9M) | (129.1M) | |
| End Period Cash Flow | 58.0M | 168.1M | 171.3M | 71.7M | 224.9M | 127.7M | |
| Change To Netincome | 438K | 4.0M | 15.0M | 14.0M | 16.1M | 16.9M |
Tarsus PharmaceuticalsI Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Tarsus PharmaceuticalsI or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Tarsus PharmaceuticalsI's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Tarsus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.54 | |
β | Beta against NYSE Composite | -0.12 | |
σ | Overall volatility | 4.16 | |
Ir | Information ratio | 0.11 |
Tarsus PharmaceuticalsI Volatility Alert
Tarsus PharmaceuticalsInc shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Tarsus PharmaceuticalsI's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Tarsus PharmaceuticalsI's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Tarsus PharmaceuticalsI Fundamentals Vs Peers
Comparing Tarsus PharmaceuticalsI's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Tarsus PharmaceuticalsI's direct or indirect competition across all of the common fundamentals between Tarsus PharmaceuticalsI and the related equities. This way, we can detect undervalued stocks with similar characteristics as Tarsus PharmaceuticalsI or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Tarsus PharmaceuticalsI's fundamental indicators could also be used in its relative valuation, which is a method of valuing Tarsus PharmaceuticalsI by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Tarsus PharmaceuticalsI to competition |
| Fundamentals | Tarsus PharmaceuticalsI | Peer Average |
| Return On Equity | -0.7 | -0.31 |
| Return On Asset | -0.36 | -0.14 |
| Operating Margin | (3.40) % | (5.51) % |
| Current Valuation | 1.07 B | 16.62 B |
| Shares Outstanding | 37.78 M | 571.82 M |
| Shares Owned By Insiders | 4.23 % | 10.09 % |
| Shares Owned By Institutions | 94.77 % | 39.21 % |
| Number Of Shares Shorted | 7.9 M | 4.71 M |
| Price To Book | 6.90 X | 9.51 X |
| Price To Sales | 77.74 X | 11.42 X |
| Revenue | 17.45 M | 9.43 B |
| Gross Profit | (17.76 M) | 27.38 B |
| EBITDA | (142.28 M) | 3.9 B |
| Net Income | (135.89 M) | 570.98 M |
| Cash And Equivalents | 245.36 M | 2.7 B |
| Cash Per Share | 9.20 X | 5.01 X |
| Total Debt | 31.73 M | 5.32 B |
| Debt To Equity | 0.09 % | 48.70 % |
| Current Ratio | 21.36 X | 2.16 X |
| Book Value Per Share | 5.76 X | 1.93 K |
| Cash Flow From Operations | (117.49 M) | 971.22 M |
| Short Ratio | 13.48 X | 4.00 X |
| Earnings Per Share | (4.62) X | 3.12 X |
| Price To Earnings To Growth | 0.28 X | 4.89 X |
| Target Price | 53.38 | |
| Number Of Employees | 244 | 18.84 K |
| Beta | 1.05 | -0.15 |
| Market Capitalization | 1.39 B | 19.03 B |
| Total Asset | 266.22 M | 29.47 B |
| Retained Earnings | (244.66 M) | 9.33 B |
| Working Capital | 219.19 M | 1.48 B |
| Net Asset | 266.22 M |
Note: Acquisition by Wahl Bryan of 12038 shares of Tarsus PharmaceuticalsI subject to Rule 16b-3 [view details]
Tarsus PharmaceuticalsI Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Tarsus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Tarsus PharmaceuticalsI Buy or Sell Advice
When is the right time to buy or sell Tarsus PharmaceuticalsInc? Buying financial instruments such as Tarsus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 795K | 4.8M | 18.4M | 19.3M | Total Assets | 178.9M | 227.9M | 266.2M | 166.0M |
Use Investing Ideas to Build Portfolios
In addition to having Tarsus PharmaceuticalsI in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cigarettes Thematic Idea Now
Cigarettes
Tobacco makers and distributors across globe. The Cigarettes theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cigarettes Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Tarsus PharmaceuticalsI Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Tarsus Stock analysis
When running Tarsus PharmaceuticalsI's price analysis, check to measure Tarsus PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus PharmaceuticalsI is operating at the current time. Most of Tarsus PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Tarsus PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Tarsus PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Tarsus PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tarsus PharmaceuticalsI. If investors know Tarsus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tarsus PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.62) | Revenue Per Share 0.594 | Quarterly Revenue Growth 0.308 | Return On Assets (0.36) | Return On Equity (0.70) |
The market value of Tarsus PharmaceuticalsInc is measured differently than its book value, which is the value of Tarsus that is recorded on the company's balance sheet. Investors also form their own opinion of Tarsus PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Tarsus PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tarsus PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Tarsus PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tarsus PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tarsus PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tarsus PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.